Ld. Dikkeschei et al., OPTIMIZATION OF A CLASSICAL AROMATASE-ACTIVITY ASSAY AND APPLICATION IN NORMAL, ADENOMATOUS AND MALIGNANT BREAST PARENCHYMA, Journal of steroid biochemistry and molecular biology, 59(3-4), 1996, pp. 305-313
The tritium water release assay, originally described for the analysis
of aromatase activity in placental tissue, was used to estimate aroma
tase activity in breast tissue samples. The lower activity in this tis
sue necessitates longer incubation times and thus optimization of the
assay conditions. To prevent oxidative and proteolytic inactivation of
aromatase, dithiothreitol and albumin were added to the incubation mi
xture. Extra NADPH, cofactor in the aromatase reaction, also improved
reaction rate in placental incubations, but after approximately 120 mi
n activity rapidly decreased. Inhibitors gradually produced during the
incubation could explain this phenomenon. Quantitative gas chromatogr
aphy-mass spectrometry (GC-MS) analyses of testosterone, oestradiol, o
estrone and androstenedione after incubation with non-labelled androst
enedione proved that a substantial amount of the substrate is converte
d into testosterone. Qualitative GC-MS steroid profiling of the incuba
tion mixture demonstrated the presence of hydroxylated oestradiol and
hydroxylated testosterone, produced during incubation, which could hav
e caused partial aromatase inhibition. The adjusted assay was used to
analyse 84 breast tissue samples, histologically classified as normal,
adenoma or carcinoma. Aromatase activity was found in 56% of all samp
les and ranged from 0.6 to 26 pmol oestrogen/g protein per hour. Aroma
tase positivity was found in 80% of the normal samples, 56% of the ade
noma samples and 48% of the carcinoma samples. Although carcinoma samp
les were less often aromatase positive than normal tissue samples chi(
2) = 4.80; P < 0.050) there was no difference in absolute aromatase ac
tivity. Because no less than approximately 50% of the carcinomas conta
ined aromatase activity and because of the non-routine character of th
e assay we conclude that it is justified to start aromatase inhibition
therapy without previous knowledge of the aromatase status. Copyright
(C) 1996 Elsevier Science Ltd.